About this episode

This episode discusses the eligibility criteria for GLP-1 medications in Australia based on a new study.

My name is Sally Block, the MJA’s news and online editor. “The MJA acknowledges the Traditional Owners and Custodians of the land on which we live and work across Australia. This podcast was recorded on the lands of the Wangal people. I pay my respects to their Elders past and present.” With the proliferation of GLP 1s globally, a new study published in the MJA aims to provide an estimate of the number of adults eligible for TGA approved medicine for chronic weight management. At least four in ten adults are eligible for the drug and hundreds of thousands are eligible for the treatment of secondary prevention of heart disease. Co-author and PhD candidate Jasmin Castrillon joins me now.

People in this episode

Host: Sally Block

Guest: Jasmin Castrillon

Topics covered

• GLP-1
• chronic weight management
• heart disease
• health eligibility
• Australia

Keywords

• GLP-1
• chronic weight management
• heart disease
• TGA
• Australia
• health
• eligibility

Mentioned in this episode

Organizations: MJA, TGA

Places: Australia, Wangal

More episodes of The Medical Journal of Australia

• Episode 604: Emergency laparotomy - a national clinical care standard · August 23, 2026 · 20 min
• Episode 602: Australia's new lung cancer screening program - how is it progressing? · August 2, 2026 · 32 min

Explore listener stats, chart rankings, contacts and more on the The Medical Journal of Australia podcast page.